Motley Fool Money cover image

An Investor’s Guide to 2026

Motley Fool Money

00:00

Novo Nordisk: GLP-1 concerns may be overdone

Emily says Novo Nordisk could be undervalued despite competition and pricing risk given strong efficacy and pipeline.

Play episode from 37:41
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app